169 related articles for article (PubMed ID: 27427275)
1. Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL.
Dawidowska M; Kosmalska M; Sędek Ł; Szczepankiewicz A; Twardoch M; Sonsala A; Szarzyńska-Zawadzka B; Derwich K; Lejman M; Pawelec K; Obitko-Płudowska A; Pawińska-Wąsikowska K; Kwiecińska K; Kołtan A; Dyla A; Grzeszczak W; Kowalczyk JR; Szczepański T; Ziętkiewicz E; Witt M
Sci Rep; 2016 Jul; 6():29427. PubMed ID: 27427275
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
Yang JJ; Cheng C; Yang W; Pei D; Cao X; Fan Y; Pounds SB; Neale G; Treviño LR; French D; Campana D; Downing JR; Evans WE; Pui CH; Devidas M; Bowman WP; Camitta BM; Willman CL; Davies SM; Borowitz MJ; Carroll WL; Hunger SP; Relling MV
JAMA; 2009 Jan; 301(4):393-403. PubMed ID: 19176441
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
4. Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia.
Zhang H; Liu AP; Devidas M; Lee SH; Cao X; Pei D; Borowitz M; Wood B; Gastier-Foster JM; Dai Y; Raetz E; Larsen E; Winick N; Bowman WP; Karol S; Yang W; Martin PL; Carroll WL; Pui CH; Mullighan CG; Evans WE; Cheng C; Hunger SP; Relling MV; Loh ML; Yang JJ
J Natl Cancer Inst; 2021 Apr; 113(4):408-417. PubMed ID: 32894760
[TBL] [Abstract][Full Text] [Related]
5. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
6. Influence of IL15 gene variations on the clinical features, treatment response and risk of developing childhood acute lymphoblastic leukemia in Latvian population.
Rots D; Kreile M; Nikulshin S; Kovalova Z; Gailite L
Pediatr Hematol Oncol; 2018 Feb; 35(1):37-44. PubMed ID: 29528261
[TBL] [Abstract][Full Text] [Related]
7. The effect of RFC G80A polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms.
Karathanasis NV; Stiakaki E; Goulielmos GΝ; Kalmanti M
Int J Lab Hematol; 2014 Aug; 36(4):425-30. PubMed ID: 24237708
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
Gupta SK; Bakhshi S; Chopra A; Kamal VK
Leuk Lymphoma; 2018 Aug; 59(8):1899-1904. PubMed ID: 29199525
[TBL] [Abstract][Full Text] [Related]
9. Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia.
Lu Y; Kham SK; Ariffin H; Oei AM; Lin HP; Tan AM; Quah TC; Yeoh AE
Br J Cancer; 2014 Mar; 110(6):1673-80. PubMed ID: 24434428
[TBL] [Abstract][Full Text] [Related]
10. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
13. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
14. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of minimal residual disease in children with acute lymphoblastic leukemia of different genetic abnormalities].
Huang SY; Jia YP; Liu GL; Zhang LP; Lu AD; Wang B
Zhongguo Dang Dai Er Ke Za Zhi; 2014 May; 16(5):494-8. PubMed ID: 24856999
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia.
Cui L; Li Z; Wu M; Li W; Gao C; Deng G
Leuk Res; 2010 Oct; 34(10):1314-9. PubMed ID: 20034668
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Davies SM; Borowitz MJ; Rosner GL; Ritz K; Devidas M; Winick N; Martin PL; Bowman P; Elliott J; Willman C; Das S; Cook EH; Relling MV
Blood; 2008 Mar; 111(6):2984-90. PubMed ID: 18182569
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]